Adjuvant immunotherapy in patients with resected GEJ cancer with high risk for recurrence
Lizzy Smyth, GI oncologist at Oxford University NHS Foundation Trust, posted on X about recent paper by her as co-author, titled “Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study.” published on ESMO Journals.
Authors: F. Lordick, M.E. Mauer, G. Stocker, C.A. Cella, I. Ben-Aharon, G. Piessen, L. Wyrwicz, G. Al-Haidari, T. Fleitas-Kanonnikoff, V. Boige, R. Lordick Obermannová, U.M. Martens, C. Gomez-Martin, P. Thuss-Patience, V. Arrazubi, A. Avallone, K.K. Shiu, P. Artru, B. Brenner, C. Buges Sanchez, I. Chau, S. Lorenzen, S. Daum, M. Sinn, B. Merelli, N.C.T. van Grieken, M. Nilsson, M. Collienne, A. Giraut, E. Smyth
“Great to see this published!
VESTIGE is a negative randomised trial with an important lesson..
Give adjuvant FLOT even when there’s residual cancer after neoadjuvant chemo.
Looking forward to the translational work.”
Elizabeth (Lizzy) Smyth is a consultant medical oncologist specializing in upper GI oncology at Oxford University NHS Foundation Trust. Her research focuses on esophagogastric cancer, with an emphasis on clinical trials and translational research. Smyth is a member of the ESMO Upper GI Faculty, serves as Chair of the Guidelines Committee, and is a member of the ESMO Council.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023